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Abstract
Background: Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for
localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not
been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate
duration of ADT for localized prostate cancer.
Methods: Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy
following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as
serious cancer cell damage or elimination, were investigated.
Results: Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0
and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT
from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group
(median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for
≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.
Conclusions: Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell
damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.
Background
The advantages of primary androgen deprivation therapy
(ADT) for localized prostate cancer continue to be con-
troversial. A population-based epidemiological study
indicated that primary ADT does not improve survival
in the majority of patients with localized prostate cancer
[1,2]. In contrast, Akaza et el. [3] demonstrated that pri-
mary ADT has favourable results for localized or locally
advanced prostate cancer in Japanese males. They
showed that the overall survival rate of Japanese males
with prostate cancer was not different from that of nor-
mal Japanese males in the same age group. Although no
evidence of benefit or sanction by guidelines has been
reported, a substantial number of patients with localized
prostate cancer receive primary ADT. In the United
States of America, rates of primary ADT use in patients
with localized prostate cancer have sharply increased,
and primary ADT has become the second most com-
mon treatment approach after surgery for localized
prostate cancer [4]. In Japan, primary ADT was admi-
nistered in 39.5% patients with stage T1-T2 prostate
cancer diagnosed in 2000 [5] and was the most common
treatment in males with localized prostate cancer. Thus,
primary ADT is a treatment option for advanced as well
as localized prostate cancer. However, an appropriate
duration of primary ADT for localized prostate cancer
has not been defined. ADT is usually continued until
disease progression or the occurrence of unacceptable
adverse events. Is long-term primary ADT, ≥10 years in
certain cases, required for treatment of localized pros-
tate cancer? Long-term ADT is associated with adverse
events such as bone fractures, diabetes, coronary heart
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mal duration for primary ADT should be defined that
not only yields long-term cancer control or a cure but
also reduces adverse events and costs and maintains
quality of life. However, few studies have addressed this
issue; therefore, it remains inconclusive. The appropriate
duration of ADT can be defined by investigating the
ADT duration required to kill most cancer cells. A use-
ful strategy to understand the effect of ADT on cancer
cells is a pathological evaluation of cancer status in
prostatectomy specimens following neoadjuvant ADT.
We explored the appropriate duration of primary ADT
for localized prostate cancer by pathologically reviewing
cancer status in radical prostatectomy specimens follow-
ing neoadjuvant ADT with maximum androgen block-
ade (MAB).
Results
Of the 68 patients, 24 (35.3%) were classified as pT0.
The clinical characteristics, duration of neoadjuvant
ADT and PSA levels of the pT0 and non-pT0 groups
are listed in Table 1.
The PSA values before and after ADT, clinical stages,
Gleason score and risk classification did not predict
conversion into pT0. The median duration of neoadju-
vant ADT in the pT0 and non-pT0 groups was 9
months and 7.5 months, respectively (p = 0.022). When
the duration of neoadjuvant ADT was divided into
before and after PSA reached < 0.2 ng/ml or its nadir,
the median duration before PSA reached < 0.2 ng/ml or
its nadir was 3 months in both the pT0 and non-pT0
groups. In contrast, the median duration after PSA
r e a c h e d<0 . 2n g / m lo ri t sn a d i rw a s5m o n t h sa n d3
months in the pT0 and non-pT0 groups, respectively. A
longer duration after PSA reached < 0.2 ng/ml or its
lowest value was significantly associated with pT0 classi-
fication (p = 0.011, Figure 1). pT0 frequency increased
with a longer duration of ADT after the PSA reached <
0.2 ng/ml or lits nadir. Five of six (83.3%) patients who
received ADT for ≥10 months after PSA reached < 0.2
ng/ml achieved pT0 (Figure 2) and this ratio was signifi-
cantly higher than that in patients treated with ADT for
shorter durations (p = 0.0099).
With a median postoperative follow-up of 31 months
(range, 4-114 months), PSA progression was observed in
one (4.2%) and nine (20.5%) patients in the pT0 and
non-pT0 groups, respectively. Patients in the pT0 group
had a tendency for longer PSA progression-free survival,
although the difference was not statistically significant
(p = 0.062) (Figure 3). Of all patients, only one in the
non-pT0 group clinically progressed and died of pros-
tate cancer 55 months following surgery.
Discussion
Although the small number of positive biopsies, low
Gleason scores (< 7) and low stages (cT1-2) may be
associated with pT0 (8), only ADT duration was indica-
tive of conversion into pT0 in the present study. The
duration of ADT, particularly after PSA reached < 0.2
ng/ml, was significantly associated with pT0. Of the six
patients who received ≥10 months of ADT after PSA
reached < 0.2 ng/ml, five (83.3%) were classified as pT0.
Whether viable cancer cells persist cannot be easily
determined even by using immunohistochemistry or
thin sections of specimens. Thus, pT0 may not be inter-
preted as the complete elimination of cancer. Koller-
mann et al. [8] did not observe a significant difference
in PSA progression-free survival between patients classi-
fied as pT0 and non-pT0. However, we observed PSA
progression in only one of 23 pT0 patients (4.3%) with a
median follow-up of 35 months, and patients in the pT0
group had a tendency for longer PSA progression-free
survival. Kitagawa et al. [9] showed that PSA progres-
sion was not observed in patients with a grade 3 patho-
logical effect, regarded as pT0, with a median follow-up
of 34.2 months. These observations indicate that pT0
Table 1 Pre-treatment clinical characteristics and
duration of ADT in the pT0 and non-pT0 groups
pT0 (N = 24) non-pT0 (N = 44) p value
Age, yr
Median 67 69 0.25
Range 56-76 54-75
PSA level, ng/ml
Median 10 11.3 0.261
Range 4.8-29.0 4.9-73.9
Clinical stage (%)
T1c 8 (33.3) 16 (36.4) 0.865
T2a 10 (41.7) 18 (40.9)
T2b 3 (12.5) 7 (15.9)
T2c 3 (12.5) 3 (6.8)
Gleason score (%)
≤ 6 7 (29.2) 12 (27.3) 0.227
7 11 (70.8) 27 (61.4)
≥ 8 0 (0.0) 5 (11.4)
Risk* (%)
Low 4 (16.7) 9 (20.5) 0.887
Intermediate 10 (41.7) 16 (36.4)
High 10 (41.7) 19 (43.2)
Duration of ADT, mo
Median 9 7.5 0.022
Range 3-19 3-29
n PSA before PRx ** (%)
< 0.2 ng/ml 24 (100) 39 (88.6) 0.219
> 0.2 ng/ml 0 5 (11.4)
* According to D’Amico et al [18]
** nadir PSA before prostatectomy
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Figure 1 Duration of ADT: total (A), before (B), and after (C) PSA reached < 0.2 ng/ml or its nadir.
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Figure 2 Number and frequency of pT0 according to duration of ADT after PSA reached < 0.2 ng/ml or its nadir.
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Page 3 of 6can be regarded as an evidence of considerable cancer
cell damage. Even when a small number of viable cancer
cells remain, those cells will not develop clinically signif-
icant cancer in all cases. Thus, durations of ADT that
induce pT0 could cause serious damage to cancer cells
and achieve long-term control of localized prostate
cancer.
Accumulated data illustrated the effect of ADT in
combination with radiation therapy or prostatectomy.
RTOG 92-02 [10] and EORTC 22961 [11] demonstrated
the survival advantage of long-term ADT (24-36
months) compared with short-term ADT (4-6 months)
in combination with radiation therapy. Because local
treatment was identical in both groups, the systemic
effect of 2-3 years of ADT could reduce or eliminate
micrometastases, as well as any residual primary cancer
cells, resulting in a better outcome. Most studies on
neoadjuvant ADT before prostatectomy did not show a
survival advantage [12], suggesting that neoadjuvant
ADT does not completely eliminate cancer cells. In
those studies, however, the duration of neoadjuvant
ADT was 3-8 months. In intermittent androgen
suppression (IAS), usually performed for localized, meta-
static, or recurrent prostate cancer, the median on-ther-
apy time is 3-9 months and PSA increases after 3-16
months of off-therapy [13]. These observations suggest
that duration of ≤ 9 months may be insufficient, but 2-3
years of ADT may considerably eliminate cancer.
Although whether 2-3 years of ADT is optimal remains
unclear, the efficacy of limited-time, not lifelong, ADT
may have the potential to obtain long-term control or
cure for prostate cancer.
Labrie et al. [14] demonstrated the possibility of a
cure with MAB of limited duration for localized pros-
tate cancer. With a median follow-up of 4.9 years (for
stage T2) and 5.6 years (for stage T3), non-PSA failure
rates were 36%, 87.5% and 91.7% for patients pre-
viously treated with MAB for 3.5-6.5 years, 6.5-10
years and 10-11.7 years, respectively. No biochemical
or clinical progression occurred in patients with loca-
lized cancer (T2) treated with MAB for ≥6.5 years.
These results indicate that long term (> 6.5 years)
continuous MAB offers the possibility of long-term
control or a possible cure for localized prostate cancer.
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Figure 3 PSA progression-free survival in the pT0 and non-pT0 groups.
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Page 4 of 6Although long-term (over 6.5 years) ADT may cure
localized prostate cancer, whether such long-term
ADT is really required remains unclear. In the study
by Labrie et al., PSA failure was defined as an elevation
of PSA > 1.0 ng/ml, which is too low to define cancer
recurrence, because benign prostate cells can also pro-
duce PSA. Following radiation therapy with or without
neoadjuvant ADT, PSA recurrence was defined as a
PSA value of ≥2.0 ng/ml above the lowest value [15].
Then, duration ≤ 6.5 years of ADT may be sufficient
to control localized cancer.
Cessation of ADT may not completely cure localized
prostate cancer that may be obtained by long-term
ADT, because pT0 does not always indicate complete
elimination of cancer cells. Prostate cancer may recur
following cessation of ADT in some patients. When
PSA increased after cessation of ADT, Labrie et al. [14]
observed a decrease of PSA in all cases by re-introduc-
tion of ADT. Re-introducing ADT can decrease the PSA
level in most patients treated with IAS, which is at least
as effective as continuous ADT [13]. These observations
indicate that a vast majority of cancer cells remain
androgen-sensitive after approximately 2 years of ADT.
Rapid progression is unlikely, even in patients whose
PSA levels rise after cessation of ADT, and patients
could be treated successfully by re-introducing ADT at
the time of recurrence. Therefore, cessation of ADT
m a yn o tr e s u l ti nap o o r e r outcome compared with
long-term continuous ADT in patients with localized
prostate cancer.
The present study had some limitations. First, as all
patients received MAB, the duration of ADT with
mono-therapy, either castration or solely anti-androgen,
is yet to be determined. Second, all patients in this
study were Japanese. The response to ADT may differ
among races, and Japanese males respond better to
ADT than Caucasian males [16]. The appropriate dura-
tion may differ among races and should be defined by
an investigation in other races. Third, the prevalence of
pT0 was higher than that in previous reports [8,9,17].
We performed pathological evaluation using only hema-
toxylin and eosin (H & E) staining; the prevalence of
pT0 may decrease if immunohistochemistry was
employed. Relatively long durations of neoadjuvant ADT
(58.8% were ≥8 months) and the race (Japanese) in our
patients may also have been associated with the higher
prevalence of pT0.
Conclusions
Our results indicate that continuous ADT with MAB for
10 months after PSA reached < 0.2 ng/ml induced a
marked therapeutic effect on cancer cells and may be a
therapeutic option for patients with localized prostate
cancer.
Methods
The ethics committee of the University of Occupational and
Environmental Health approved the study. Sixty-eight con-
secutive patients with clinically localized prostate cancer,
who underwent a retropubic radical prostatectomy follow-
ing neoadjuvant ADT between March 2001 and June 2010
at our institute, were reviewed retrospectively. Clinical sta-
ging was determined by a digital rectal examination, trans-
rectal ultrasound, computed tomography scan and a bone
scan. Pre-treatment risk categories were classified according
to D’Amico et al. [18]. For neoadjuvant ADT, MAB with
LH-RH agonist (leuproreline acetate or goserelin) and an
anti-androgen (375 mg/day of flutamide or 80 mg/day of
bicalutamide) was continued until prostatectomy. PSA level
was assessed monthly until the prostatectomy.
Following surgery, no patient received adjuvant ther-
apy and PSA was monitored every 3 months for 1 year,
every 4 months for the next 2 years and every 6 months
thereafter. PSA recurrence was defined as two consecu-
tive values > 0.2 ng/ml. CTs and bone scans were per-
formed when indicated.
Prostatectomy specimens were fixed in 10% buffered
formalin and serially cut into 3-5-mm thick sections,
representing transverse planes parallel to the initial api-
c a la n db a s a ls e c t i o n s .T h ea p i c a la n db a s a lt r a n s v e r s e
margins were sectioned perpendicularly to assess the
prostatic apical and basal margins. Each prostate slide
was processed into a whole mount section. One slide
was routinely sectioned at 7 μm per block and stained
with H & E. Specimens in which no cancer cells were
detected or all cancer cells examined had non-viable fea-
tures, such as nuclear pyknosis or karyolysis, were classi-
fied as pT0. Thus, pT0 suggested maximum damage to
cancer cells. The pathological results of the prostatect-
omy specimens were grouped into pT0 and non-pT0.
Differences in pre-treatment clinical characteristics
and in the duration of ADT between the pT0 and non-
pT0 groups were analyzed with the Mann-Whitney U-
test and the c
2 test. An estimate of PSA progression fol-
lowing prostatectomy was calculated using the Kaplan-
Meier method, and the significant difference between
the pT0 and non-pT0 groups was calculated using the
log-rank test; p < 0.05 was considered significant.
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